Irritable Bowel Syndrome Treatment Market Report and Forecast 2023-2031

The global irritable bowel syndrome treatment market size attained a value of about USD 2.39 billion in 2022. The market is anticipated to grow at a CAGR of 10.13% during the forecast period of 2023-2031. The global irritable bowel syndrome treatment market share is anticipated to achieve a value of USD 5.71 billion by 2031.

Irritable Bowel Syndrome Epidemiology

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder that affects the large intestine. The prevalence of IBS varies across different regions of the world, with an estimated global prevalence of around 10-15% of the population.

IBS can occur at any age, but it is most commonly diagnosed in people under the age of 50. It affects both men and women equally, although women tend to be diagnosed more frequently than men.

The prevalence of IBS varies widely across different regions of the world, with higher rates in developed countries. The condition is estimated to affect around 10-15% of the population globally, with higher rates in North America and Europe. In contrast, the prevalence is lower in Asia and Africa.

There are several lifestyle factors that can increase the risk of developing IBS, including stress, a sedentary lifestyle, and a diet high in processed foods and low in fibre. Other risk factors include a family history of the condition and a history of gastrointestinal infections.

In terms of prognosis, IBS is a chronic condition that can have a significant impact on quality of life. The symptoms of IBS, which include abdominal pain, bloating, and changes in bowel habits, can be managed with appropriate treatment. However, there is currently no cure for the condition.

In conclusion, IBS is a common gastrointestinal disorder that affects around 10-15% of the population globally. The condition is more prevalent in developed countries and is more commonly diagnosed in women than men. Lifestyle factors such as stress, a sedentary lifestyle, and a poor diet can increase the risk of developing IBS. While there is currently no cure for the condition, appropriate treatment can help manage symptoms and improve quality of life for affected individuals.

Global Irritable Bowel Syndrome Treatment Market Segmentations

Market Breakup by Type

IBS-C

• IBS-C Market
• Linzess/Constella
• Amitiza
• Others

IBS-D

• Xifaxan
• Viberz
• Others

Market Breakup by Application

• Cardiology
• Urology and Nephrology
• Oncology
• Gastroenterology
• Others

Market Breakup by End User

• Hospitals
• Clinics and Research Laboratories
• Others

Irritable Bowel Syndrome Treatment Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Global Irritable Bowel Syndrome Treatment Market Scenario

The global market for irritable bowel syndrome (IBS) treatment is expected to grow significantly in the coming years, driven by factors such as the increasing prevalence of the condition, a growing demand for effective treatment options, and the development of new and innovative therapies.

Antispasmodics are the most commonly used drugs for the treatment of IBS and are expected to continue to dominate the market during the forecast period. However, other drug classes such as antidepressants and laxatives are also expected to gain traction due to their efficacy in managing the symptoms of IBS.

Geographically, the market is expected to experience significant growth in North America and Europe due to the high prevalence of IBS in these regions and the presence of well-established healthcare infrastructure. However, the Asia Pacific region is expected to witness the highest growth rate due to the increasing prevalence of the condition and a growing demand for effective treatment options.

In conclusion, the global market for IBS treatment is expected to witness significant growth in the coming years due to the increasing prevalence of the condition and the development of new and innovative treatment options. The market is expected to be driven by factors such as the growing demand for effective treatments, the expanding product portfolios of key players in the market, and the increasing awareness about the condition among healthcare professionals and patients.

Key Players in the Global Irritable Bowel Syndrome Treatment Market

The report gives an in-depth analysis of the key players involved in the global irritable bowel syndrome market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Takeda Pharmaceutical Company Limited
• Astellas Pharma
• Ironwood Pharmaceuticals, Inc
• AstraZeneca
• Sebela Pharmaceuticals Inc
• Bausch Health
• Salix Pharmaceuticals
• Abbott Laboratories
• Johnson & Johnson Services Inc
• GlaxoSmithKline plc
• Ono Pharmaceutical Co., Ltd
• Pfizer Inc
• LEXICON PHARMACEUTICALS, INC

This product will be delivered within 5-7 business days.